Summary

GOLD 2026 is the 6th major revision of the global strategy for COPD diagnosis, management, and prevention. Key updates include lowering the threshold for GOLD group E to include even one moderate exacerbation, a new Disease Activity framework, clarified initial vs follow-up pharmacological algorithms, new biologic therapy guidance (dupilumab, mepolizumab), updated RSV/pneumococcal/influenza vaccination, completely revised exacerbation and multimorbidity chapters, and a new chapter on AI and emerging technologies. Diagnosis remains anchored on post-bronchodilator FEV1/FVC < 0.7 with active case-finding (not population screening) endorsed.

Key Recommendations

Confirm COPD diagnosis with post-bronchodilator FEV1/FVC < 0.7 by spirometry in symptomatic patients with risk factor exposure; pre-bronchodilator spirometry may be used to exclude COPD.
Classify patients using the ABE assessment: Group A (low symptoms, 0 exacerbations), Group B (high symptoms, 0 exacerbations), Group E (≥1 moderate or severe exacerbation in prior year, regardless of symptoms).
Initial pharmacotherapy: Group A — a bronchodilator; Group B — LABA+LAMA; Group E — LABA+LAMA, and consider LABA+LAMA+ICS if blood eosinophils ≥300 cells/µL.
Use blood eosinophil count to guide ICS: strongly favors ICS if eos ≥300 cells/µL or ≥2 moderate exacerbations/year; against ICS if eos <100 cells/µL or history of mycobacterial infection.
Escalate to LABA+LAMA+ICS for patients with exacerbations on LABA+LAMA when eos ≥100 cells/µL; consider dupilumab (if chronic bronchitis) or mepolizumab if exacerbations persist on triple therapy with eos ≥300 cells/µL.
Offer pulmonary rehabilitation to all symptomatic patients (Groups B and E); initiate within 4 weeks of hospital discharge for exacerbation to reduce readmission and mortality.
Prescribe LTOT (>15 hr/day) only for severe resting hypoxemia: PaO2 ≤55 mmHg or SaO2 ≤88%, or PaO2 55–60 mmHg with cor pulmonale/polycythemia.
Vaccinate all COPD patients: annual influenza, COVID-19, pneumococcal (PCV20 or PCV21 preferred), RSV (age ≥50 with risk or ≥75 universally), Tdap, and zoster (age >50).
Treat moderate/severe exacerbations with SABA ± SAMA, oral prednisone 40 mg/day × 5 days, and antibiotics × 5 days when purulent sputum, prior positive culture, or mechanical ventilation is required.
Use NIV as first-line ventilatory support for hypercapnic respiratory failure (PaCO2 ≥45 mmHg, pH ≤7.35); reduces intubation, hospital stay, and mortality.
Smoking cessation with combined counseling plus pharmacotherapy (varenicline, bupropion, or NRT) is the single most effective intervention to alter COPD natural history; e-cigarettes are not recommended for cessation.
Actively screen for and treat multimorbidities — cardiovascular disease, heart failure, lung cancer (annual LDCT for eligible smokers), osteoporosis, anxiety/depression, OSA, and GERD — as they independently affect prognosis.

Thresholds & Doses

Diagnostic spirometry: post-bronchodilator FEV1/FVC < 0.7
GOLD severity by FEV1 % predicted: GOLD 1 ≥80%, GOLD 2 50–79%, GOLD 3 30–49%, GOLD 4 <30%
Symptom thresholds: mMRC ≥2 or CAT ≥10 = ‘more symptoms’ (Group B/E)
Group E definition: ≥1 moderate OR ≥1 severe exacerbation in prior year (new 2026 threshold, lowered from ≥2)
Blood eosinophil thresholds for ICS: <100 cells/µL = against ICS; ≥100 to <300 = favors; ≥300 = strongly favors
Biologic eligibility: blood eosinophils ≥300 cells/µL with exacerbations on triple therapy (dupilumab 300 mg q2 weeks; mepolizumab 100 mg q4 weeks)
LTOT criteria: PaO2 ≤55 mmHg (7.3 kPa) or SaO2 ≤88%; or PaO2 55–60 mmHg with pulmonary hypertension/cor pulmonale/hematocrit >55%
Oxygen duration: >15 hours/day (24 hr not superior to 15 hr per 2024 evidence)
In-flight target: PaO2 ≥6.7 kPa (50 mmHg); supplemental O2 typically 3 L/min nasal cannula
Exacerbation systemic corticosteroid: prednisone 40 mg/day × 5 days
Exacerbation antibiotics: 5 days when sputum purulence + ≥2 cardinal symptoms, or mechanical ventilation required
NIV indication: PaCO2 ≥45 mmHg with pH ≤7.35; long-term NIV considered if persistent PaCO2 >53 mmHg post-hospitalization
Rome classification of exacerbation severity uses: dyspnea VAS, RR (<24 vs ≥24), HR (<95 vs ≥95), SaO2 (≥92% vs <92%), CRP (<10 vs ≥10 mg/L)
Lung cancer screening: annual LDCT age 50–80 with ≥20 pack-years, current smoker or quit within 15 years
Pulmonary rehabilitation: minimum 6–8 weeks, supervised exercise ≥2x weekly; initiate within 4 weeks post-discharge
Endobronchial valve eligibility: post-BD FEV1 15–45% with marked hyperinflation, intact fissures/no collateral ventilation
Lung transplant referral: BODE 5–6, PaCO2 >50 mmHg, PaO2 <60 mmHg, FEV1 <25%
Indoor temperature targets: keep bedrooms >18°C in cold weather; living spaces <32°C and sleeping <24°C in heat
Alpha-1 antitrypsin: test all COPD patients; level <20% normal suggests homozygous deficiency; augmentation typically when FEV1 35–60% predicted

Citations

Chapter 1 — Definition, pathogenesis (GETomics), and taxonomy/etiotypes of COPD
Chapter 2, Figure 2.13 — GOLD ABE Assessment Tool with new Group E threshold of ≥1 moderate exacerbation
Chapter 3, Figures 3.7–3.9 — Initial vs follow-up pharmacological treatment algorithms
Chapter 3, Figure 3.10 — Factors favoring/against ICS use including blood eosinophil thresholds
Chapter 3, Figure 3.11 — Evidence for biologic therapy (dupilumab BOREAS/NOTUS; mepolizumab MATINEE)
Chapter 3, Figure 3.19 — Therapies with mortality reduction evidence (triple therapy, smoking cessation, PR, LTOT, NIV, LVRS)
Chapter 4, Figure 4.2 (Rome classification) — Severity grading of COPD exacerbations
Chapter 5, Figures 5.1–5.6 — Multimorbidity 4Ms framework and follow-up evaluation panels
Chapter 6 — Artificial Intelligence and telehealth in COPD (new chapter)
Appendix 3 — Pharmacotherapy evidence overview including bronchodilators, ICS, biologics, and adherence